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SUMMARY. This study was conducted to understand the
symptomatology, attitudes, and behaviours of chronic hep-
atitis B (CHB) patients in the USA. CHB patients enrolled in
this study were recruited through multiple methods,
including newspaper advertisements. Interviews were con-
ducted in multiple languages, and all participants had a
history of CHB infection for at least 6 months. Patients with
documented human immunodeﬁciency virus or hepatitis C
virus coinfection were excluded from data analyses, resulting
in a total study population of 258 respondents who com-
pleted interviews between April and June 2004. The
majority of monoinfected patients were male (57%) and non-
Asian (92%, including 52% Caucasian, 32% African
American and others). Length of diagnosis was 5.8 years for
all participants (9.1-year Asian and 5.1-year non-Asian).
Ninety-ﬁve per cent of CHB patients reported symptoms
of differing severity in the 12 months prior to the survey.
The most common symptoms included fatigue/loss of energy
(90%) and loss of appetite (79%). Non-Asian patients de-
scribed greater symptomatology, and were more likely than
Asians to consider CHB an overriding concern in their daily
activities. Patients were treated either currently or previ-
ously with interferon (IFN) described greater symptomatol-
ogy than those treated without IFN. Survey results indicate
that CHB patients may have greater symptomatology than
recognized. Disease perceptions and treatment attitudes dif-
fer between Asian and non-Asian ethnic groups, with the
former appearing to be more accepting and less concerned
about the disease. Additional research about CHB symp-
tomatology and health attitudes by ethnicity is needed to
ensure that individuals with CHB are educated on the po-
tential health risks and the availability of current treatment
options.
Keywords: chronic hepatitis B, socio-economic, symptom-
atology, survey.
INTRODUCTION
Chronic hepatitis B (CHB) is associated with progressive liver
disease, including cirrhosis, decompensated cirrhosis and
hepatocellular carcinoma (HCC) [1,2]. End-stage liver dis-
ease resulting from CHB is associated with well-recognized
clinical manifestations and costs to the US healthcare sys-
tem. [3]. However, to date, the overall impact of CHB on
quality of life, including health attitudes and symptomatol-
ogy, has not been well described.
Approximately12millionpeople(4.9%)havebeenexposed
to/infected with hepatitis B virus (HBV) in the USA [4]. It is
estimated that over half of the 1.25 million individuals with
CHB in the US are Asian/Paciﬁc Islander (API) Americans
[4,5]. According to Centers for Disease Control (CDC) ﬁgures
from 2002, the incidence of CHB is 7% among API Ameri-
cans, compared with 0.1–0.5% among Caucasian, Hispanic
and African-Americans. Furthermore, the incidence in for-
eign-born API Americans mirrors that in Asia-Paciﬁc and
sub-Saharan African countries (9% vs 10%, respectively),
while that among US-born APIs is 1.4% [5]. These data
suggest that Asian immigrants are disproportionately im-
pacted by CHB in the USA.
The ultimate risk of disease progression in CHB patients is
high. Up to 40% of infected patients will develop cirrhosis,
liver failure or HCC [6]. Death from chronic liver disease
occurs in 15–25% of CHB patients [7]. In contrast to the US
pattern of transmission through infected needles and blood,
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mother to infant. Horizontal transmission within families
also occurs in children under 10 years of age [8–10]. Thus,
Asians with HBV infection usually acquire their infection at
a much younger age and are therefore at much greater risk
of developing long-term complications of the infection by the
fourth or ﬁfth decade of life, approximately 20 years earlier
than American patients who usually do not acquire HBV
until the second or third decade of life [11,12].
Despite the risk of disease progression, CHB is perceived as
relatively asymptomatic in patients with compensated liver
function. Whether the disease is truly asymptomatic or
symptoms go unrecognized is not well described. According
to the CDC, about 30% of HBV-infected persons have no
overt signs or symptoms [7]. The Asian Liver Center at
Stanford University and the Hepatitis B Foundation suggest
this number may be even greater, with 69% of infected
people experiencing no symptoms or having unrecognized
symptoms. Hepatitis B is therefore frequently described as a
silent infection.
Quality of life data for CHB is scarce compared with other
viral infections such as hepatitis C virus (HCV) and human
immunodeﬁciency virus (HIV), with most studies being
cross-sectional or small in numbers [13,14]. Kunkle et al.
[15] observed that depression levels in a small group of 50
Korean American patients with CHB were positively corre-
lated with liver enzyme levels. Additionally, a small com-
munity-based survey of 56 Korean Americans highlighted
concerns such as misunderstanding HBV transmission and
fear of stigmatization or ostracism that appeared to result in
depression combined with chronic fatigue (Kim and Hann,
pers. comm.). Given the high prevalence and mortality of
hepatitis B infection, it is critical to better understand the
symptomatology and impact of chronic HBV infection. This
study employed a patient survey to assess symptomatology
experienced by CHB patients in the USA, and to characterize
patients attitudes towards CHB and their general health.
METHODS
This was an industry-sponsored study that was conducted
between April and June of 2004, and recruited self-identiﬁed
patients in seven major US cities with a high prevalence of
CHB. A history of CHB infection for at least 6 months was
required to participate in the survey. A variety of recruit-
ment approaches were employed, including physician-dis-
tributed postcards, advertisements in metropolitan
newspapers and hepatitis-related Web sites, and ﬂyers posted
in shopping malls and other high-trafﬁc locations. Surveys
were translated into Spanish, Korean and Chinese. Study
participants were remunerated equally for essentially an
hours worth of time. Participants were not aware that this
was an industry-sponsored study; they were, however,
aware that the study was being sponsored by a ﬁrm that was
interested in understanding how people live with CHB. Study
sponsors adhered to the CASRO (Council of American Sur-
vey Research Organizations) privacy policy for protection of
the participants identity, and, per the policy guidelines,
identity of the participants was not revealed to them.
The survey comprised 59 questions with ﬁxed-response
choices. Questions were categorized by demographics, cur-
rent health status including symptomatology, attitudes
towards overall health, attitudes towards hepatitis B and
general lifestyle. Given the speciﬁc interest in understanding
the symptomatology and attitudes towards CHB, patients
with HIV coinfection or HCV coinfection were excluded from
these analyses. Prior ribavarin use was considered to be
indicative of HCV coinfection, and patients with a history of
ribavarin use were excluded from this study. Based on self-
reported diagnosis and treatment history, patients were
stratiﬁed according to ethnicity (Asian vs non-Asian) and
treatment status (never treated vs current or past treatment
with interferon [IFN] vs current or past treatment without
IFN). IFN use is associated with signiﬁcant side effects, and
patients were stratiﬁed by treatment status to understand
the extent to which reported symptoms differ for patients
treated with IFN vs those treated without IFN. Information
about the patients pre-treatment clinical condition, clinical
response to therapy, medical history and concomitant illness
was not collected.
Participants were asked to rate the severity of symptoms
and impact of symptoms on daily life using a 5-point scale.
This scale was generated from an exploratory qualitative
research project with hepatitis B patients as well as industry-
standard Likert scales for research projects. Conversations
with patients suggested that the spectrum of symptoms
ranged from a scale of frequency (how often a symptom is
experienced) to severity and impact on life. With that
knowledge, a 1–5 scale to denote breaks within this spec-
trum that is consistent with validated research methodolo-
gies was chosen [16]. Furthermore, a 5-point or odd-number
scale was chosen to allow for a neutral opinion.
Statisticalcomparisonswereperformedbetweensubgroups
ofinterestinapairwisefashionandevaluatedatthetwo-sided
alpha level of 0.05 without adjustment for multiple compari-
sons. A chi-squared testwas used for the analysis of difference
in percentages. A t-test was used for the analysis of difference
in mean scores between groups.
RESULTS
Demographic and background characteristics
A total of 376 patients with CHB completed the survey.
Patients with documented HIV coinfection or with HCV
coinfection including prior ribavirin use were excluded from
the data analyses, resulting in a total study population of
258 respondents. Of these, the majority of patients were
male (57%) and Caucasian (52%), with a median age of
43.8 years (Table 1).
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similar to that of the average US CHB patient, according to
available data (ISIS Hep B Monitor). This study also recruited
a similar proportion of Caucasian and African-American
patients compared with that of the US CHB population,
although a lower than expected number of Asian patients
participated.
Stratiﬁcation by ethnicity and treatment status
No signiﬁcant demographic differences were observed
among Caucasian, African-American or other patients;
hence, these individuals were grouped together as non-
Asian. Individual Asian groups (Chinese, Japanese and
Vietnamese) were also pooled. Patients were then stratiﬁed
according to ethnicity (Asian vs non-Asian) and treatment
status (never treated vs current or past treatment with IFN vs
current or past treatment without IFN).
Asian study participants were diagnosed with CHB for a
signiﬁcantly longer period than non-Asian patients (9.24 vs
5.34 years, respectively) (Table 2). Asian patients were more
likely than non-Asians to be educated to college level or
higher, and married. Fewer Asian than non-Asian patients
surveyed were employed and Asians had a lower income
than non-Asians. Signiﬁcantly fewer Asians than non-
Asians were under the care of a physician (25% vs 63%,
respectively), and in line with this ﬁnding, signiﬁcantly more
Asian than non-Asian patients had never been treated for
CHB (70% vs 45%, respectively; treatment here does not
include the use of traditional Chinese medicine). Prior use of
herbal and/or traditional Chinese medicine was signiﬁcantly
more common among Asian than non-Asian patients (40%
vs 13%, respectively).
Greater numbers of treated patients (with or without IFN)
compared with never treated patients were under the care of
a physician and had health insurance, were educated to
college level or higher, were employed, and had a higher
annual income (Table 2).
Symptoms experienced in previous 12 months
In this survey population, a wide range of general (e.g.
fatigue, headache) and liver-speciﬁc (e.g. jaundice and liver
pain) symptoms were reported in the population as a whole
irrespective of ethnicity. Almost all study participants (95%)
reported experiencing symptoms within the last 12 months.
Fatigue/loss of energy, loss of appetite and nausea were the
three most common symptoms, reported by 90%, 79%, and
78% of study participants, respectively.
Fewer Asian subjects reported experiencing individual
symptoms in the previous 12 months, except for liver pain,
which was higher in Asian than in non-Asian patients
(Fig. 1a). Differences in incidence of most symptoms were
not signiﬁcant between ethnic groups; however, nausea,
muscle/joint pain and mental confusion were signiﬁcantly
less frequent in Asian patients than in non-Asian patients.
Patients who were never treated were signiﬁcantly less
likely to report experiencing individual symptoms in the
previous 12 months compared with patients currently or
previously treated with or without IFN, except for fatigue/loss
of energy and vomiting, which were comparable between
both groups (Fig. 1b). Although greater symptomatology
was seen among treated patients, untreated patients still had
relatively high levels of symptoms, with >50% reporting
experiencing each symptom assessed in the previous
12 months. For the majority of symptoms, greater percent-
ages of patients treated with IFN experienced the symptom in
the last 12 months compared with those treated without IFN.
Severity of symptoms
Among all study participants, fatigue/loss of energy and
muscle/joint pain were reported as the most severe symp-
toms, scoring a mean of 2.5 and 2.1, respectively, using a
scale where 1 = not at all severe, 2 = not very severe,
3 = somewhat severe, 4 = very severe and 5 = extremely
severe (data not shown). Subjects not experiencing a given
Table 1 Demographic and background
characteristics of study population
compared with that of the US chronic
hepatitis B (CHB) patient based on ISIS
data
Total study
population
(n = 258)
Study population
under MD care*
(n = 138)
ISIS Hep B
monitor
(n = 700)
Gender, n (%)
Male 148 (57) 79 (57) (69)
Female 110 (43) 59 (43) (31)
Mean (±SD) age, years 44 ± 10 43 ± 10 43 ± 12
Race, n (%)
Caucasian 133 (52) 87 (63) (44)
African American 82 (32) 32 (23) (24)
Asian 20 (8) 5 (4) (26)
Other (incl. Hispanic) 23 (9) 14 (10) (8)
*Under MD care = visits a physician every 6 months or more often for CHB; ISIS
now called Synovate Healthcare.
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Asian patients reported more severe symptoms in every in-
stance compared with Asian patients; these differences were
signiﬁcant for all symptoms except for liver pain, dark-col-
oured urine, sexual dysfunction and fainting (Fig. 2).
Impact of symptoms on daily life
Among all participants, fatigue/loss of energy and muscle/
joint pain were reported to have the greatest impact on daily
life, scoring a mean of 2.62 and 2.20, respectively, on a 5-
point scale where 1 = not at all, 2 = a little bit, 3 = mod-
erately, 4 = quite a bit and 5 = extremely. Subjects not
experiencing a given symptom were assigned a score of 0.
Non-Asian patients frequently reported a greater impact on
their daily lives than Asian patients, with 60% of all symp-
toms measured reaching statistical signiﬁcance between the
two groups (Fig. 3).
Lifestyle attitudes
There were differences observed between the Asian and non-
Asian populations in this study with regard to their attitudes
towards daily living and lifestyle. Signiﬁcantly more Asian
Table 2 Demographic and background characteristics of monoinfected chronic hepatitis B (CHB) study population by ethnicity
and treatment status
Ethnicity Treatment status
Total
(n = 258)
Non-Asian
(n = 238)
Asian
(n = 20)
Never treated
(n = 120)
Treated with
interferon (IFN)
(n = 80)
Treated,
no IFN
(n = 58)
Mean (±SD) age, years 44 ± 10 44 ± 10 44 ± 14 45 ± 10 43 ± 10 43 ± 11
Gender, n (%)
Male 148 (57) 134 (56) 14 (70) 66 (55) 50 (62.5) 32 (55)
Female 110 (43) 104 (44) 6 (30) 54 (45) 30 (37.5) 26 (45)
Race, n (%)
Caucasian 133 (52) 133 (56) – 54 (45) 44 (55) 35 (60)
African American 82 (32) 82 (35) – 44 (37) 25 (31) 13 (22)
Asian 20 (8) – 20 (100) 14 (12) 3 (4) 3 (5)
Other (incl. Hispanic) 23 (9) 23 (10) – 8 (7) 8 (10) 7 (12)
Mean length of time ( ± SD)
diagnosed with CHB, years
5.6 ± 4.4 5.3 ± 4.2 9.2 ± 9.2
* 5.2 ± 4.3 6.2 ± 4.9 5.8 ± 4.1
Under physician care, n (%)
Yes 154 (60) 149 (63)
* 5 (25) 46 (38)*** 63 (79) 45 (78)
No 99 (38) 86 (36) 13 (65)
* 73 (61) 13 (16) 13 (22)
Treatment, n (%)
Currently treated 93 (36) 91 (38)
* 2 (10) – 58 (73) 35 (60)
Previously treated 45 (17) 41 (17) 4 (20) – 22 (28) 23 (40)
Never treated 120 (47) 106 (45) 14 (70)
* 120 (100) – –
Herbals/TCM, n (%)
Currently use 47 (18) 45 (19) 2 (10) 19 (16) 15 (19) 13 (22)
Previously used 40 (16) 32 (13) 8 (40)
* 19 (16) 10 (13) 11 (19)
Never used 171 (66) 161 (68) 10 (50) 82 (68) 55 (69) 34 (59)
Had a liver biopsy, n (%) 57 (22) 54 (23) 3 (15) 23 (19) 19 (24) 15 (26)
Have health insurance, n (%) 189 (73) 176 (74) 13 (65) 71 (59)*** 71 (89) 47 (81)
Married, n (%) 87 (34) 77 (32) 10 (50) 35 (29) 32 (40) 20 (35)
Education, n (%)
High school or less 87 (34) 83 (35) 4 (20) 49 (41) 22 (28) 16 (28)
Some college or more 171 (66) 155 (65) 16 (80) 71 (59) 58 (73) 42 (72)
Employed, n (%) 198 (77) 187 (79)
* 11 (55) 84 (70)** 68 (85) 46 (79)
Mean household income, ( ± SD) $000s 42 ± 26 43 ± 26 36 ± 10 37 ± 26** 48 ± 25 44 ± 26
*P < 0.05 Asian vs non-Asian.
**P < 0.05 never treated vs treated with IFN.
***P < 0.05 never treated vs either treatment arm.
TCM, traditional Chinese medicine.
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72%) and happy with their lives (85% vs 56%) (Table 3).
On the other hand, signiﬁcantly more non-Asians than
Asians believed that they could take charge of their life (82%
vs 55%), and worried a lot (58% vs 30%). In all, there were
signiﬁcant differences in lifestyle attitudes in more than three
quarters of the categories assessed between the Asian and
non-Asian populations.
A
B
Fig. 1 (A) Symptoms experienced in
previous 12 months by ethnicity
(n = 258), Fig. 1. (B) Symptoms expe-
rienced in previous 12 months by
treatment status (n = 258).
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In this section of the questionnaire, subjects were asked to
comment on general health attitudes, interaction with their
physicians or extended healthcare provider and community.
The subjects perception of their health was mostly positive
as was the relationship with their physicians. In fact, over
50% strongly agreed or somewhat agreed with 11 out of 13
of the statements included in this section. However, signiﬁ-
cantly more Asians (65%) than non-Asians (18%) reported
difﬁculties in ﬁnding certain types of healthcare providers.
In addition, signiﬁcantly more Asian than non-Asian
participants felt that they were not well informed of their lab
test results. Interestingly, signiﬁcantly more non-Asian
Fig. 3 Impact of symptoms on daily life
severity of symptom: 0 = no given
symptom, 1 = not at all, 2 = a little bit,
3 = moderately, 4 = quite a bit,
5 = extremely.
Fig. 2 Severity of symptoms by ethnic-
ity. Severity of symptom: 0 = no given
symptom, 1 = not at all severe, 2 = not
very severe, 3 = somewhat severe,
4 = very severe, 5 = extremely severe.
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only a small percentage of patients were not conﬁdent of
their doctors knowledge of the right medications for them,
the percentage was signiﬁcantly higher in non-Asian pa-
tients (32%) than in Asian patients (10%) (Table 4).
Attitudes towards CHB and its treatment
Study subjects were asked to consider the relevance of CHB
from a personal and societal standpoint. There was great
discrepancy in attitudes between the Asian and non-Asian
populations with 10 out of 14 categories revealing a sig-
niﬁcant difference between the two arms. Overall, Asians
appeared to be more accepting of the disease, as exempliﬁed
by the fact that 85% did not think that CHB made them
different from other people and 90% did not feel guilty who
had the disease. This attitude was also reinforced by the
number of Asians (80%) who indicated that CHB did not
affect their dating habits. On the other hand, more non-
Asian patients were concerned about developing liver dis-
ease and liver cancer, and reported an impact of CHB on
various aspects of their lifestyle, including looking at life
differently, re-evaluating their lifestyle, being scared of CHB,
feeling guilty, being overwhelmed by CHB, feeling that they
did not deserve CHB, dating less, and thinking ﬁrst of CHB
when they wake (Table 5).
DISCUSSION
End-stage liver disease resulting from CHB is associated with
well-recognized clinical manifestations and costs to the US
healthcare system. However, to date, the impact of CHB on
quality of life, including health attitudes and symptomatol-
ogy, has not been well described. This is perhaps because of
the long-held perception that CHB is relatively asymptomatic
or silent in patients with compensated liver function.
This diverse, cross-sectional study suggests that CHB is
more symptomatic than has previously been recognized with
95% of participants reporting symptoms in the previous
12 months. Symptoms were reported frequently in both
Asian and non-Asian populations; however, there was a
signiﬁcant difference in the majority of symptoms experi-
enced between the arms with respect to those patients who
received treatment and those who did not. Fatigue/loss of
energy, loss of appetite and nausea were the three most
common symptoms, reported by 90%, 79% and 78% of
study participants, respectively. Of particular interest,
symptomatology was greater in non-Asian compared with
Asian patients and in currently or previously treated patients
in comparison with never-treated patients. Symptoms re-
ported in this survey, however, were mild, having less than
moderate impact on daily life, which might have even led to
under-reporting and/or under-detection of symptoms.
Interestingly, there seemed to be a socio-economic impact
on treatment as signiﬁcantly more non-Asians than Asians
were under physician care. This was also reﬂected in the fact
that signiﬁcantly more non-Asians were employed than
Asians. Not surprisingly, there was a signiﬁcant difference in
health insurance coverage among patients who had never
been treated compared with those who were being treated
with or without IFN, again reﬂecting a socio-economic
aspect of this disease.
Table 3 Lifestyle attitudes by ethnicity
% Reporting agree strongly or somewhat
Total
(n = 258)
By ethnicity
Non-Asian
(n = 238)
Asian
(n = 20)
A good nights sleep is important to me 88 87 100*
I believe you can take charge of your life 80 82* 55
I tend to be easy-going 74 72 90*
More often than not, I go with my gut
feeling when I have to make a decision
67 69* 45
I am happy with my life 59 56 85*
I tend to worry a lot 56 58* 30
I like to pamper myself 57 60* 25
I put my needs before the needs of others 42 44* 15
I often feel depressed 41 43* 15
I spend a lot of time with support groups 35 37* 10
I am a sensitive person 68 68 65
I tend to be an emotional person 64 66* 45
At my work, I dont want people to
know Im not feeling well
54 54 55
I have to lead two lives 39 40 25
*P < 0.05.
48 H.-W. Hann et al.
 2007 The Authors
Journal compilation  2007 Blackwell Publishing LtdPatients attitudes, knowledge and perception of CHB may
inﬂuence their acceptance of CHB and their reported symp-
toms. Asian patients reported a lesser impact of most
symptoms on their daily lives and a greater degree of
acceptance of the disease compared with non-Asian patients,
which may be a key factor in the lower reporting of symp-
toms and associated impact on their daily life. Signiﬁcant
differences in lifestyle attitudes between the Asian and non-
Asian populations were observed in more than three quar-
ters of the lifestyle categories assessed, which lead to the
conclusion that these lifestyle attitudes may impact the
reporting of, and the signiﬁcance of, symptoms arising from
CHB.
A more accepting attitude towards CHB could conceivably
lead to slower entry into the healthcare system and account,
in part, for presentation later in the natural history of the
Table 4 Attitudes towards health and physicians by ethnicity
% Reporting agree strongly or somewhat
Total
(n = 258)
By ethnicity
Non-Asian
(n = 238)
Asian
(n = 20)
I trust my doctor to prescribe the best things for me 78 79 65
I actively seek health-related information 73 74* 55
I am comfortable communicating with my doctor 71 72 60
My doctor keeps me informed of my lab test results 71 72* 50
I cant ﬁnd a dentist or other types of doctor to treat me 22 18 65*
Looking good is really important to me 77 76 90
A positive attitude can help overcome physical disease 79 79 80
My family and friends are supportive of my health needs 74 73 80
I visit doctors regularly to ensure good health 64 63 75
My doctor speaks the same language as me 65 65 65
My doctor listens to me and values my input
in treatment choices
62 63 55
My doctor understands me 62 63 50
Doctors really dont know what medications work for me 30 32* 10
*P < 0.05.
Table 5 Attitudes towards chronic hepatitis B and its treatment by ethnicity
% Reporting agree strongly or somewhat
Total
(n = 258)
By ethnicity
Non-Asian
(n = 238)
Asian
(n = 20)
I am concerned with developing liver disease 85 87* 65
I look at life differently as I found out I have Hep B 70 73* 40
Living with Hep B has caused me to re-evaluate my lifestyle 69 71* 40
Im just like other people–Hep B doesnt make me different 55 52 85*
I am scared of Hep B 62 65* 30
I did not deserve to get Hep B 59 62* 25
I feel completely overwhelmed about dealing with Hep B 52 55* 15
I am dating less now that I have Hep B 43 45* 20
Hep B makes me feel guilty 40 43* 10
Hep B is the ﬁrst thing I think of when I wake up 32 34* 10
I am worried about developing complications of liver disease 79 80 65
I worry about getting liver cancer 73 74* 55
I am conﬁdent they will ﬁnd a cure for Hep B in my lifetime 63 63 65
I do not like to talk with anyone about my Hep B 58 58 55
*P < 0.05.
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the disease (70%), did not feel guilty who had the disease
(90%), and were not led to re-evaluate their lifestyle (60%)
could be interpreted either as this population being in denial
regarding the severity of the disease, or that Asian partici-
pants did not have easy or adequate access to information
regarding the disease.
The physician–patient relationship, as shown in this
study, was less strong between doctors and patients from the
Asian community when compared with non-Asian subjects
and this may also contribute to a lower reporting of symp-
tomatology in the former group. Furthermore, the ﬁnding
that Asian patients were less inclined to actively seek health-
related information (despite more Asian patients being edu-
cated to college level or higher) is consistent with previous
surveys reporting a lack of awareness among Asians of CHB
and its consequences [17,18]. These ﬁndings suggest that
CHB-treating physicians may need to devote more attention
to patient symptomatology and case histories to better
understand the impact of CHB in a culturally sensitive
fashion.
Not surprisingly, symptomatology between treated and
untreated patients differed to some extent. Overall, greater
numbers of treated patients (currently or previously, with or
without IFN) reported experiencing symptoms in the last
12 months, compared with never-treated patients. In gen-
eral, greater numbers of patients treated with IFN experi-
enced symptoms compared with those treated without IFN.
The higher symptomatology observed in treated patients
may be due to patients with symptoms being more likely to
seek and/or receive treatment. Irrespective of the reason for
the high frequency of symptoms in the treated population,
it is striking to note that over 50% of never-treated patients
reported each symptom within the previous 12 months.
This relatively high degree of symptomatology among never-
treated patients likely reﬂects symptoms attributable to CHB
itself. Given that many of the symptoms reported in this
study are more constitutional than liver-speciﬁc in nature,
they may be related to chronic viral infection per se or HBV-
related ﬂares rather than to the effects of HBV on the liver.
Though a control group of non-HBV-infected patients was
not studied, these data reveal that a high proportion of un-
treated CHB patients are experiencing signiﬁcant symptom-
atology. Therefore, physicians should routinely monitor CHB
patients for constitutional symptoms given their prevalence
and substantial impact on daily activities.
This was a cross-sectional analysis, a limitation of which
was that improvement or worsening of patients symptoms
over time was not observed. Another possible limitation was
that the self-identiﬁed study population could over-represent
individuals concerned about their medical condition and/or
individuals with greater symptomatology. Another limita-
tion was that HCV-coinfected patients who were excluded
from this study were solely identiﬁed on the basis of prior
ribavarin use; patients treated with IFN were not excluded
from the study. As IFN can be used to treat both HBV and
HCV infections, there is a possibility that some of the subjects
included in our analyses might have been coinfected with
HCV. Also, clinical evaluation of HBV DNA levels was be-
yond the scope of this study; consequently, correlation of
symptomatology to viral load and outcome of antiviral
therapy could not be determined.
The low enrollment of Asian patients in this study was
unexpected; despite concentrated efforts, recruitment of
Asian patients was more challenging than that of Caucasian
and African-American patients. This could be due to several
factors, including potential social stigma associated with
HBV infection, more passive acceptance of CHB, and/or
conﬂicts with work schedules (many Asian study partici-
pants were self-employed). More research to address these
issues is required.
In conclusion, this study suggests that CHB may be
associated with greater symptomatology than currently
recognized, and that patient perceptions of disease and atti-
tudes about treatment may differ based on individual eth-
nicity and/or treatment experience. Further investigation of
CHB symptomatology and its effect on patient perceptions
and attitudes towards the disease state is warranted. There
also appears to be a need to develop formalized measurement
scales similar to the ones currently being used for HIV/HCV
symptomatology studies. Future research using such vali-
dated scales will further enhance the understanding of CHB
symptomatology.
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